Pfizer Inc.'s allegations Johnson & Johnson illegally thwarted biosimilar competition to its blockbuster arthritis treatment Remicade (infliximab) will stay alive.
A federal court refused J&J’s request to toss the claims, finding Pfizer sufficiently alleged J&J engaged in anticompetitive pricing policies to dissuade hospitals and providers from purchasing Pfizer’s biosimilar competitor Inflectra. The merits of the claims will be fleshed out as the case moves forward, Judge J. Curtis Joyner of the U.S. District Court for the Eastern District of Pennsylvania said.
The ruling is notable because it comes within the context of the first antitrust lawsuit to emerge over biosimilars. ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.